A chicken gene orthologous to human leptin receptor (LEPR) has been characterized and found 30 to be active in leptin signaling in vitro in response to a variety of recombinant leptins and leptin-31 containing blood samples. However, the endogenous ligand of chicken LEPR (cLEPR) -the 32 putative chicken leptin -has been reported by us and others to be undetectable at the DNA, 33 mRNA, protein and activity levels. These reports have raised questions as to cLEPR's role. Here 34 we analyzed the effects of a pegylated superactive mouse leptin antagonist (PEG-SMLA) in 35 chicken. We showed that the leptin antagonist efficiently and specifically blocks leptin signaling 36 through the cLEPR in vitro. The effect of the leptin antagonist was then studied in vivo by daily 37
Introduction 45 46
The mammalian leptin receptor (LEPR) (Tartaglia et al., 1995) , a class I cytokine receptor, was 47 2003; Friedman-Einat et al., 1999; Hen et al., 2008; Pitel et al., 2010; Sharp et al., 2008) , as well as the 76 aforementioned functional assays in cultured cells (Adachi et al., 2008; Hen et al., 2008; Yosefi et al., 77 2010) , have failed to reveal the leptin gene, mRNA, protein or activity in chicken samples. 78
In other non-mammalian vertebrates such as fish, lizards and frogs, highly divergent leptin and 79 LEPR genes have been characterized with ~30% sequence similarity, or less (Boswell et al., 2006; 80 Johnson et al., 2000; Kurokawa and Murashita, 2009; Kurokawa et al., 2008; Liu et al., 2010; Spanovich et 81 al., 2006) . Despite this low sequence similarity, cross-binding between the known leptins and LEPR from 82 various sources has been reported in our and others' laboratories (Crespi and Denver, 2006; Hen et al., 83 2008; Niv-Spector et al., 2005) . These reports are compatible with the predicted structures of the known 84 leptins and leptin-binding domains in the LEPRs (Crespi and Denver, 2006; Prokop et al., 2012) showing 85 high structural similarities, although with an increased variations in binding properties in fish with multiple 86 leptin proteins (Prokop et al., 2012) . 87
In the current study, a further step in the effort to reveal the role of cLEPR was taken by using a 88 long-acting leptin antagonist recently developed in our laboratory (Elinav et al., 2009; Mela et al., 2012; 89 Niv-Spector et al., 2012) . Since cross-reactivity of the cLEPR with divergent types of leptin, such as 90 human and frog, has been well established (Crespi and Denver, 2006; Hen et al., 2008; Niv-Spector et al., 91 2005), we expected that injection of leptin antagonist would block, and thereby reveal the activity of 92 cLEPR in chickens. 93
94

Materials and Methods 95 96
Animals 97
Male Leghorn chicks (Gallus gallus Lohman) were purchased from a local husbandry (Mekorit, 98 Hasolelim, Israel) at 1 day of age and maintained at the ARO Volcani Center in Bet Dagan, Israel. 99
Lighting and temperature conditions were set to the recommendations of the Lohman breeding company 100 (Lohmann GB, Worcester, UK). Food (Brown and Sons, Hod Hasharon, Israel) was formulated according 101 to National Research Council (1994) recommendations. Food and water were provided ad libitum. After 102 brooding, the chickens were moved to individual cages. All animal procedures were carried out in 103 accordance with the institutional animal care committee's approved protocol. 104 105 106
Leptin antagonist 107
The leptin antagonist (PEG-SMLA) described by us previously (Elinav et al., 2009; Mela et al., 108 2012; Niv-Spector et al., 2012; Shpilman et al., 2011 ) is a pegylated superactive mouse leptin mutant 109 (L23D/L39A/D40A/F41A) that exhibits high affinity to mammalian LEPRs due to the L23D mutation 110 (Shpilman et al., 2011) . 111
112
Leptin bioassay 113
Leptin activity was measured using a bioassay consisting of HEK-293 cells expressing exogenous 114 full-length cLEPR cDNA (Hen et al., 2008) and the firefly luciferase gene under the control of a trimer of 115 the STAT3-binding element. This STAT3 responsive promoter derived from interferon regulatory factor 1, 116 precedes the herpes simplex virus thymidine kinase minimal promoter in the reporter construct (Rosenblum 117 et al., 1998) . The assay was done as described before (Hen et al., 2008; Marikovsky et al., 2002; Yosefi et 118 al., 2010) . Briefly, cells were plated in 48-well tissue-culture plates (Nunc, Danyel Biotech, Rehovot, 119 Israel) at a concentration of 2 x 10 5 cells per well and a final volume of 300 ml of DMEM (Gibco/BRL). 120
The following day, medium was replaced with fresh DMEM or with medium containing either human 121 leptin or interferon αA (IFNA2), either alone or in combination with the indicated doses of the leptin 122 antagonist. After 4 h incubation at 37 o C and 5% CO 2 , the medium was aspirated, and the cells were lysed 123 by adding 100 μl Promega cell lysis reagent (Biological Industries, Beit-Haemek, Israel) Luciferase 124 activity was measured using the TD20e luminometer (Turner Design, Mountain View, CA, USA). To determine whether our well established leptin antagonist (Benoit et al., 2013; Chapnik et al., 2013; Niv-140 Spector et al., 2012; Shpilman et al., 2011) , which blocks mammalian LEPRs, also blocks the cLEPR, we 141 used our previously described leptin bioassay in HEK-293 cells (Hen et al., 2008; Marikovsky et al., 2002; 142 Yosefi et al., 2010) (Fig.1) . HEK-293 cells expressing exogenous cLEPR and luciferase reporter genes, 143
were stimulated with human leptin and with IFNA2, both activating the reported gene through the cLEPR 144 or an endogenous IFNR, respectively (Hen et al., 2008; Rosenblum et al., 1998) . The dose-response curves 145 of luciferase activation by leptin and IFNA2, were used to select a concentration within the linear range 146 (Fig. 1, A and B) for stimulation of the cLEPR in the presence of increasing amounts of leptin antagonist 147 (Fig. 1, A' and B'). Luciferase activation by 625 pM human leptin was completely blocked by 10 4 ng/ml of 148 the antagonist and significant partial inhibition could be observed at 10 3 and 2 x 10 3 ng/ml (Fig. 1A') . 149
Under the same assay conditions, the leptin antagonist did not block or inhibit activation of luciferase by 150 IFNA2 (Fig. 1B') . This efficient and specific inhibition of cLEPR activation is compatible with the reported 151 resemblance of the tertiary structures of known leptins and binding domains in the known LEPRs (Denver 152 et al., 2011; Prokop et al., 2012) , and with our and others' previous results of cross-binding of various 153
leptins to a variety of LEPRs (Crespi and Denver, 2006; Hen et al., 2008; Niv-Spector et al., 2005) . 154
155
Administration of leptin antagonist to chickens 156
To explore the leptin antagonist's potential to induce appetite and enhance body growth rate in 157 chickens, as we previously showed in mice (Benoit et al., 2013; Chapnik et al., 2013; Elinav et al., 2009; 158 Niv-Spector et al., 2012; Niv-Spector et al., 2010; Shpilman et al., 2011) , lean male chickens at 2 wk of age 159 were subjected to daily administration of the leptin antagonist. As demonstrated in Fig. 2 , during the 10 d 160 of treatment, the pegylated leptin antagonist had no observable effect on BW, feed intake, feed efficiency 161 (as indicated by feed conversion rate) or fat accumulation. 162
Injection of 10 mg antagonist/kg BW is expected to give a circulating concentration of about 800 μg/ml 163 (based on an estimated blood volume of 8% of total BW). This concentration is 16 times higher than that 164 leading to complete blockage of the cLEPR signaling in vitro at the presence of 50 ng/ml leptin, which 165 corresponds to the circulating level of leptin in obese subjects (Silha et al., 2003) . Moreover, the same 166 preparation of the antagonist (Chapnik et al., 2013; Solomon et al., 2013) as well as other preparations 167 (Elinav et al., 2009; Niv-Spector et al., 2012; Shpilman et al., 2011 ) and a very similar administration 168 protocols led to about 30 to 50% increase in BW and feed intake in rodents at d 10 of treatment, as well as 169 an increase in food intake and fat deposition. The effect on BW and feed intake were significant from the 170 first measurement (the first or second d of treatment). Therefore, the results in Fig. 2 can be taken as an 171 indication that in a sharp contrast to the mammalian LEPR, the cLEPR is not implicated in the control of 172 food intake, body growth and fat deposition. 173
We have previously shown that blocking of leptin activity in rodent by the pegylated leptin antagonist is 174 mediated both by blocking its transport to the brain and direct blocking of LEPR signaling in the brain 175 (Elinav et al., 2009 ). In addition, we have demonstration relatively high levels of the short form of the 176 cLEPR in the choroid plexus (the main site of leptin transport to the brain (Zlokovic et al., 2000) ), and of 177 the long form in the hypothalamus (Horev et al., 2000) . This pattern of cLEPR expression, which is highly 178 similar the LEPR expression in mice (Tartaglia et al., 1995) , indicate its accessibility to blocking by the 179 leptin antagonist at the same sites as in mice. 180
181
Does the cLEPR have a ligand? 182
The unsuccessful efforts to identify the ligand of the cLEPR is detailed in the introduction. While the 183 erroneous identification of the chicken leptin has been removed from GenBank, a bird's leptin has recently 184 been annotated in Taeniopygia guttata (Gene ID: 101233729), suggesting that leptin is expressed in these 185 birds. However, this gene sequence did not show significant similarity neither to the published chicken 186 genome sequence nor to our own full chicken genome sequencing (at ~20-fold coverage, obtained with an 187
Illumina HiSeq2000 sequencing platform, data not shown). It should be noted that the template DNA for 188 our genome sequencing was of the exact chicken strain used for injection in the current study. Hence, the 189 lack of detectable leptin like sequences in the genome of these chickens is compatible with the finding of 190 no effect of the leptin antagonist on the indicated energy balance aspects. Nevertheless, it is likely that this 191 receptor, which has retained its functional properties through evolution, may have another role (yet to be 192 determined) that is not equivalent to the crucial function of the mammalian ortholog in the control of 193 appetite and adipose homeostasis. 194
195
Conclusions 196
Our experiments indicate that inhibition of the cLEPR in vivo using a highly potent antagonist does 197 not affect feed intake, feed efficiency or fat accumulation in Leghorn chickens. The observation is in line 198 with our previous reports demonstrating no circulating leptin activity in fat or lean birds (Hen et al., 2008; 199 Yosefi et al., 2010) , as well as with the indication from our and others' laboratories that leptin gene or gene 200
products cannot be detected in avian species (Friedman-Einat et al., 1999; Pitel et al., 2010; Prokop et al., 201 2012; Sharp et al., 2008) 
